197 related articles for article (PubMed ID: 34659896)
1. MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy.
Oshi M; Gandhi S; Huyser MR; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Endo I; Takabe K
Am J Cancer Res; 2021; 11(9):4421-4437. PubMed ID: 34659896
[TBL] [Abstract][Full Text] [Related]
2. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.
Oshi M; Gandhi S; Angarita FA; Kim TH; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3611-3627. PubMed ID: 34354863
[TBL] [Abstract][Full Text] [Related]
3. Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer.
Xie X; Chauhan GB; Edupuganti R; Kogawa T; Park J; Tacam M; Tan AW; Mughees M; Vidhu F; Liu DD; Taliaferro JM; Pitner MK; Browning LS; Lee JH; Shen Y; Wang J; Ueno NT; Krishnamurthy S; Hortobagyi GN; Tripathy D; Van Laere SJ; Bartholomeusz G; Dalby KN; Bartholomeusz C
Cancer Res Commun; 2023 Jun; 3(6):1078-1092. PubMed ID: 37377604
[TBL] [Abstract][Full Text] [Related]
4. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.
Speers C; Zhao SG; Kothari V; Santola A; Liu M; Wilder-Romans K; Evans J; Batra N; Bartelink H; Hayes DF; Lawrence TS; Brown PH; Pierce LJ; Feng FY
Clin Cancer Res; 2016 Dec; 22(23):5864-5875. PubMed ID: 27225691
[TBL] [Abstract][Full Text] [Related]
5. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
[TBL] [Abstract][Full Text] [Related]
6. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
[TBL] [Abstract][Full Text] [Related]
7. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Angarita FA; Yan L; Matsuyama R; Zsiros E; Ishikawa T; Endo I; Takabe K
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086518
[TBL] [Abstract][Full Text] [Related]
8. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
[TBL] [Abstract][Full Text] [Related]
9. High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer.
Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371179
[TBL] [Abstract][Full Text] [Related]
10. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
Li G; Yang M; Zuo L; Wang MX
Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
[TBL] [Abstract][Full Text] [Related]
11. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Lin ML; Park JH; Nishidate T; Nakamura Y; Katagiri T
Breast Cancer Res; 2007; 9(1):R17. PubMed ID: 17280616
[TBL] [Abstract][Full Text] [Related]
12. Maternal embryonic leucine zipper kinase in tumor cells and tumor microenvironment: An emerging player and promising therapeutic opportunity.
Tang BF; Yan RC; Wang SW; Zeng ZC; Du SS
Cancer Lett; 2023 Apr; 560():216126. PubMed ID: 36933780
[TBL] [Abstract][Full Text] [Related]
13. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
[TBL] [Abstract][Full Text] [Related]
14. Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer.
Das A; Prajapati A; Karna A; Sharma HK; Uppal S; Lather V; Pandita D; Agarwal P
Chem Biol Interact; 2023 May; 376():110443. PubMed ID: 36893906
[TBL] [Abstract][Full Text] [Related]
15. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K
Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202
[TBL] [Abstract][Full Text] [Related]
16. MELK expression correlates with tumor mitotic activity but is not required for cancer growth.
Giuliano CJ; Lin A; Smith JC; Palladino AC; Sheltzer JM
Elife; 2018 Feb; 7():. PubMed ID: 29417930
[TBL] [Abstract][Full Text] [Related]
17. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer.
Oshi M; Patel A; Wu R; Le L; Tokumaru Y; Yamada A; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
NPJ Breast Cancer; 2022 Aug; 8(1):92. PubMed ID: 35945417
[TBL] [Abstract][Full Text] [Related]
19. Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.
Bollu LR; Shepherd J; Zhao D; Ma Y; Tahaney W; Speers C; Mazumdar A; Mills GB; Brown PH
NPJ Breast Cancer; 2020; 6():2. PubMed ID: 31909186
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
Edupuganti R; Taliaferro JM; Wang Q; Xie X; Cho EJ; Vidhu F; Ren P; Anslyn EV; Bartholomeusz C; Dalby KN
Bioorg Med Chem; 2017 May; 25(9):2609-2616. PubMed ID: 28351607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
